Amylyx Pharmaceuticals Inc (AMLX)

[CEO_BC]

$AMLX

Relyvrio treatment a year costs 159K$ per patient. There are 100K patient in US in need for such drug treatment. We did 110M revenue in last quarter reported at 40K$ drug costs which make it to 3K patient… from a market size of 100K (3% adoption)

The market competition for ALS is way higher than for Wolframe Syndrome.

Wolframe Syndrome has 25K patient market size in US and 25K patient in Europe. Europe has a strong need to a better drug for it. There is a strong potential that we reach quick 500M-1B$ revenue a year in the Wolframe Syndrom drugs Market.

I would assume that the company will share soon a market potential and forecast for the treatment of Wolframe Syndrome.

We were at $12 SP before we sold anything. The potential here is still way higher than $12. The larger strategic investors know this too. Expect that some will increase further holding at this price level.